The efficacy and safety of fluconazole in the treatment of oesophageal candidiasis in patients with the acquired immunodeficiency syndrome (AIDS) was assessed in 36 patients. Fluconazole, 200 mg orally, was given on the first day, followed by 100 mg daily for 4 weeks. Clinical and mycological evaluation was performed in 31 patients at the end of treatment and 24 were also assessed after 8 weeks of starting treatment. In 1 patient fluconazole was discontinued, 5 patients were lost to follow-up and 6 patients died during the study.
Introduction
Oesophageal candidiasis occurs in about 90% of acquired immunodeficiency syndrome (AIDS) patients.' The conventional but unsatisfactory treatment for Candida oesophagitis in AIDS was parenteral amphotericin in short-course therapy of 8-10 days2 despite the need for intravenous administration and marked drug toxicity. Ketoconazole has also been useful to treat oesophageal candidiasis and it has been proposed3 as the treatment of choice for this condition. Problems associated with ketoconazole include ketoconazole-resistant Candida strains,' impaired gastrointestinal absorption secondary to the hyposecretory gastropathy that occurs in AIDS patients,57 the risk of hepatitis,i the interaction with other drugs, particularly rifampicin,9 and the unavailability of an intravenous preparation.
The new triazole agents (fluconazole, itraconazole) may overcome some of these difficulties."0-2 Fluconazole is effective in treatment of deep and superficial Candida infections in both healthy and immunosuppressed rats. 13"14 Oropharyngeal candidiasis in AIDS patients responds satisfactorily to fluconazole'5 as may oesophageal candidiasis. '6 We describe the results of treatment with fluconazole of oesophageal candidiasis in a series of AIDS patients.
Materials and methods
Thirty six AIDS patients of mean age 28 years (25 male and 11 female), diagnosed according to criteria established by the Centers for Disease Control,'7 were studied. The most important risk factor for AIDS was illicit drug use (31 patients). In 15 the diagnosis of AIDS had been established in the preceding year (11 cases) or before (4 cases). Thirty one patients had a total of 38 human immunodeficiency virus (HIV)-associated opportunistic infections or neoplasias. Previous liver disease was documented in 6 patients and 15 patients had elevated liver enzymes values at entry. Twenty six patients were also receiving potentially hepatotoxic therapy including isoniazid and rifampicin (7 patients), sulphonamides (9), zidovudine (11) and benzodiazepines (15 Endoscopic diagnosis of oesophageal candidiasis was required for inclusion of a patient in the study. Patients were excluded from study if: (i) aged less than 18 years; (ii) pregnant or breast feeding; (iii) had active liver disease with aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) and alkaline phosphatase (AP) values above three times the upper normal limits, and bilirubin higher than 51.3 ,Lmol/l; (iv) previous hypersensitivity to azole derivatives; (v) concomitant use of other antifungal or liver enzyme inducing drugs (barbiturates, coumarin anticoagulants, oral hypoglycaemics or cyclosporin) or (vi) administration of any other investigational agent.
Patients were treated for 4 weeks, and followedup for 8 weeks after starting treatment ( Figure 1 ). Fluconazole, 200 mg orally, was given on day one followed by 100 mg daily for 4 weeks. Follow on prophylactic fluconazole, 200 mg once weekly, was given in 22 patients. Clinical assessment was performed daily in patients admitted to the hospital and weekly for outpatients.
Methods HIV antibody was determined by ELISA'8 and Western Blot'9 methods. Lymphocyte subset determinations were performed by indirect immunofluorescence method.20 Candida serology was performed by haemagglutination (Lab. Roche) and immunoprecipitation (Lab. Pasteur). A Fuji FP3 endoscope with a Fuji Mod K24 16R biopsy punch was used for oesophagoscopy. Three tissue samples were obtained; two ofthem were processed for pathological examination and the third was cultured for fungi in Sabouraud's dextrose agar medium with and without chloramphenicol. The culture was incubated at 30°C and 37°C, and fungus identification was performed using the Vitek system.2' Patients were monitored closely for adverse reactions. Student t test applying Yate's correction was used for statistical analysis.
Results

Clinical course and mycological results
Thirty six patients entered the study; 31 completed the treatment period and 24 the follow-up. Six patients died ofa non-Candida opportunistic infection during the study, two in the treatment period. biopsy revealed Mycobacterium tuberculosis infection. Thus fluconazole toxicity was unlikely, but cannot be excluded. In the patients whose liver function tests became abnormal no changes in their fluconazole therapeutic regime were required. At follow-up liver function tests tended to return to normal. No correlation was found between liver enzyme abnormalities and the patients' age, sex, weight, previous liver disease, or abnormal liver enzyme values, ethanol intake, concomitant infections or drug treatment. A marked decrease in CD4 + cell count and the simultaneous administration of more than 3 drugs seemed to confer a higher risk of possible fluconazole-induced hepatotoxicity, although this was not statistically significant (P <0.1).
Discussion
The present report is the most extensive one published as yet on fluconazole treatment for oesophageal candidiasis in AIDS patients. In all cases, the endoscopic findings, the histological picture and the mycological culture confirmed the efficacy offluconazole. Clinical cure was rapid with symptoms of oesophageal involvement resolving within the first week of treatment in 87% of patients and in all patients after 10 days of therapy.
After successful fluconazole therapy asymptomatic fungal colonization of the oropharynx is commonly observed in AIDS patients22 and may cause recurrence of clinical illness. In our series (Table II) oropharyngeal colonization was present in 43% at the end of the treatment period and some of the most azole-resistant Candida species were recovered. The early appearance of relapses after completing fluconazole treatment in our initial 2 patients prompted us to devise a prophylactic regime. Oral fluconazole, 200 mg once a week, was given to a further 22 patients and none presented relapses during the follow-up period. If this simple prophylactic regime proves to be effective in more extended series, this will represent an obvious advantage over existing preventive regimens for Candida oesophagitis. This regimen would increase patients' compliance and decrease the risk of interaction with drugs used for prophylaxis and treatment of other opportunistic infections in AIDS patients.
Fluconazole has shown little toxicity in experimental fungal infection models and clinical studies.23 Increases of liver enzymes2426 have been reported during fluconazole therapy but in only 16 (0.4%) of the first 4057 patients treated with fluconazole was it necessary to discontinue treatment due to significant hepatotoxicity (Pfizer Central Research -Data on file). In our series, an unexpectedly high incidence (47%) of mild (15 patients) to moderate (1 patient) increase in liver enzymes values was observed. Several factors must be taken into account in considering the high incidence of hepatic abnormalities observed in our patients. A higher incidence of adverse drug effects has been reported to occur in AIDS patients. 27 Moreover, most of our patients were in advanced stages of the disease as demonstrated by the severe decrease in CD4 lymphocyte count and the high mortality rate (6 out of 36) observed during the time of the study. Other opportunistic infections which might have involved the liver coexisted in 31 patients. Potentially hepatotoxic drugs were administered to 26 patients. Thus, patients in this series constitute a subgroup with a greater tendency to develop hepatic abnormalities than non-AIDS (or even HIV-positive with good general health status) patients with superficial mycoses who are not receiving other potentially hepatotoxic drugs and who usually receive smaller doses of fluconazole.
The rapidity of the clinical response in our treated patients as well as the results from other studies on AIDS patients with oropharyngeal candidiasis treated with lower doses (50 mg/day) of fluconazole for shorter periods,28'29 suggests that with treatment for less than 4 weeks it might be possible to achieve cure in most patients.
We conclude that 4 weeks offluconazole is a very effective treatment for oesophageal candidiasis in AIDS patients. Shorter treatment periods (i.e. 7-10 days) may be eventually efficacious. Further studies are necessary to establish the most effective follow-up prophylactic regimen for oesophageal candidiasis in AIDS. Such studies should also examine the potential for hepatotoxicity and predictive risk factors.
